Your session is about to expire
← Back to Search
Treatment for Muscular Dystrophy (GRASP-01-001 Trial)
N/A
Waitlist Available
Led By Nicholas Johnson, MD
Research Sponsored by Virginia Commonwealth University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 12 months
Awards & highlights
Summary
Limb Girdle Muscular Dystrophy comprise a group of disorders made up of over 30 mutations which share a common phenotype of progressive weakness of the shoulder and hip girdle muscles. While the individual genetic mutations are rare, as a cohort, LGMDs are one of the four most common muscular dystrophies. The overall goal of project 1 is to define the key phenotypes as measured by standard clinical outcome assessments (COAs) for limb girdle muscular dystrophies (LGMD) to hasten therapeutic development.
Eligible Conditions
- Muscular Dystrophy
- Limb-Girdle Muscular Dystrophy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Forced vital capacity (FVC)
Change in activity limitations
Change in mobility
+10 moreFind a Location
Who is running the clinical trial?
Nationwide Children's HospitalOTHER
347 Previous Clinical Trials
5,229,146 Total Patients Enrolled
Washington University School of MedicineOTHER
1,970 Previous Clinical Trials
2,308,543 Total Patients Enrolled
University of IowaOTHER
460 Previous Clinical Trials
891,754 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger